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Summary Background This phase I study evaluated the
pharmacokinetics and pharmacodynamics of CEP-11981, an
oral vascular endothelial growth factor (VEGF) tyrosine ki-
nase inhibitor, in patients with advanced, relapsed, or refrac-
tory solid tumors. Methods Oral CEP-11981 dose escalations
followed a modified Fibonacci sequence (from 3.0 to 4.2, 5.9,
11.8, 19.7, 29.6, 41.4, 55.0, 73.0, 97.4, and 126.6 mg/m2). The
maximum-tolerated dose (MTD), dose-limiting toxicities
(DLTs), tumor response, and safety were evaluated. Results
CEP-11981 was tolerated at doses between 3.0 and 97.4 mg/
m2. The MTD of CEP-11981 was determined to be 97.4 mg/
m2, with DLTs observed at the 126.6 mg/m2 dose. The DLTs
were grade 4 neutropenia in 1 patient and grade 3 T-wave
inversion with chest heaviness and fatigue in 1 patient. All 3
events resolved on stopping CEP-11981. The most frequently
reported adverse events of any grade were fatigue, nausea,
diarrhea, decreased appetite, abdominal pain, back pain,
vomiting, constipation, headache, dizziness, and dyspnea.
Treatment-related grade 3/4 neutropenia was observed in the
highest-dose cohorts (2 patients at 97.4 mg/m2 and 1 patient at
126.6 mg/m2), indicating some off-target inhibition. VEGF
inhibition was greatest in the higher-dose groups. Although no
patient experienced complete or partial response, 44 %
patients achieved stable disease when measured at ≥6 weeks,
which occurred more frequently in cohorts receiving
≥73.0 mg/m2. Conclusions In patients with recurrent or re-
fractory solid tumors, disease stabilization was achieved. De-
spite acceptable tolerability of CEP-11981 at theMTD, further
development by the sponsor has ceased.
Keywords Dose-finding study .Multitargeted inhibition .
Safety profile . Tie-2 . Tyrosine kinase inhibitor . Vascular
endothelial growth factor
Introduction
Angiogenesis plays an essential role in the development and
progression of cancer [1]. Numerous proangiogenic signaling
cascades have been identified, such as the vascular endothelial
growth factor (VEGF) ligands and their respective receptors
(R), VEGFR-1/Flt-1, VEGFR-2/KDR, and VEGFR-3/Flt-4
[2–4]. Notably, the VEGFR-2/KDR subtype in particular
plays a primary role in promoting angiogenesis.
Bevacizumab, a humanized monoclonal anti-VEGF A an-
tibody, abrogates signal transduction of the proangiogenic
VEGFR-1 and VEGFR-2 [5]. Bevacizumab, alone and in
combination, has demonstrated the ability to block or attenu-
ate tumor growth and in some tumor types, improve overall
survival (OS) and/or progression-free survival (PFS) [6–10].
However, the magnitude and duration of benefit has generally
been modest because of numerous mechanisms of intrinsic
and/or acquired resistance to antiangiogenic therapy [11–14].
Because tumor cells engage a wide range of angiogenic fac-
tors, agents that target a single factor or ligand-receptor axis
may be insufficient [14]. With the objective of improving
clinical outcomes and providing an oral medication for ad-
vanced cancer, antiangiogenic therapies that inhibit multiple
signaling pathways, including other proangiogenic targets,
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were developed [13]. These include tyrosine kinase inhibitors
(TKIs) that target the VEGF signaling pathway. However, the
first approved VEGFR-TKIs (eg, sunitinib, sorafenib) lack
specificity, and it has been postulated that the abrogation of
the other signaling pathways would promote adverse events
not associated with the main angiogenic signaling pathways.
Therefore, other VEGFR-TKIs with improved potency and
specificity for additional targets including proangiogenic
platelet-derived growth factor (PDGF) and its receptors,
PDGFR-α and PDGFR-β have potential clinical advantages
[15, 16].
A proangiogenic signaling pathway and potential therapeu-
tic target is the Tie-2 receptor and its ligands, angiopoietin
(Ang)-1 and Ang-2 [17–19]. Studies suggest that the VEGFR
and Tie-2 pathways are synergistic and promote a greater
degree of angiogenesis versus either pathway alone [11,
20–22]. Therefore, it has been proposed that for the optimal
inhibition of tumorigenesis, both VEGFR and Tie-2 should be
simultaneously inhibited [21, 23]. Solid tumor cell-line exper-
iments demonstrated that Tie-2 upregulates Ang-2 [19] and
animal models have shown that relapsing tumors upregulate
Ang-1 [11]. In a human melanoma xenograft model, inhibi-
tion of both the VEGFR-2 and Tie-2 pathways versus
VEGFR-2 alone reduced the amount of angiogenesis and the
tumor burden [23]. The potential value of a multitargeted
inhibitor was recently borne out in a phase III study of rego-
rafenib monotherapy in patients with treatment refractory
metastatic colorectal cancer that showed modestly improved
OS (6.4 versus 5.0 months; P=0.0052) [24].
CEP-11981 is an orally active multitargeted VEGFR-TKI
that inhibits VEGFR-1, VEGFR-2, Tie-2, fibroblast growth
factor receptor-1, proto-oncogene c-SRC, and Aurora A (half
maximal inhibitory concentration [IC50] of 3, 4, 22, 13, 37,
and 42 nM, respectively) [25]. Preclinical studies have shown
that CEP-11981 exhibits promising permeability, metabolic
stability, and pharmacokinetic properties across multiple spe-
cies [25]. Studies of pharmacologic activity across angiogen-
esis assays, animal tumor models, and human tumor models
have shown sustained, dose-related antiangiogenic and anti-
tumor inhibition [25]. This phase I study was conducted to
determine the maximum-tolerated dose (MTD), dose-limiting
toxicities (DLTs), pharmacokinetics, and pharmacodynamics
of CEP-11981 in patients with advanced, relapsed/refractory
solid tumors, with the objective to identify the recommended
dose of CEP-11981 for use in a phase II study.
Methods
Patient selection
Adult patients (≥18 years) who had histologically or cytolog-
ically confirmed relapsed or refractory solid tumor that was
unresponsive or poorly responsive to accepted treatment mo-
dalities, a life expectancy of at least 12 weeks, and an Eastern
Cooperative Oncology Group (ECOG) performance score of
0–2 were included in this study. Eligible patients had a normal
neurological examination and were fully recovered from any
prior surgical procedures or had reversible side effects of prior
cancer therapy. Patients were excluded if they had abnormal
hematologic (absolute neutrophil count [ANC]<1500/mm3,
platelet count<100,000/mm3, or hemoglobin <9 g/dL), hepat-
ic (bilirubin>1.5 times the upper limit of normal [ULN],
alanine aminotransferase [ALT] or aspartate aminotransferase
[AST]>2.0 times the ULN in the absence of known hepatic
metastases, or ALT or AST>3.0 times the ULN in the pres-
ence of known hepatic metastases), or kidney functioning
(creatinine value>1.5 mg/dL). Other reasons for exclusion
included cerebral metastases, known hypersensitivity to gela-
tin or lactose monohydrate, preexisting coagulopathy, recent
hemoptysis, gross hematuria, gastrointestinal bleeding, histo-
ry of a clinically significant cardiovascular or cerebrovascular
event within 6 months of study entry, or blood pressure
>150 mmHg systolic or 90 mmHg diastolic with medication.
Patients were excluded if they were currently receiving war-
farin or heparin therapy; received any other antineoplastic
treatment for solid tumors (hormonal treatment permitted)
within the previous 4 weeks; received an investigational drug
within the previous 4 weeks; or received a human cytochrome
P450 (CYP) 1A2, CYP2C8, or CYP3A4 inducer within the
previous 4 weeks.
Female patients who were pregnant or lactating were ex-
cluded from this study. All men capable of producing off-
spring and all women of childbearing potential were required
to use reliable contraception.
Study design and endpoints
This was an open-label, nonrandomized, multicenter, dose-
escalation phase I study of CEP-11981 in patients with ad-
vanced, relapsed/refractory solid tumors. The study was con-
ducted in accordance with Good Clinical Practice: Consoli-
dated Guidance approved by the International Conference on
Harmonisation, and applicable national and local laws and
regulations and approved by appropriate Independent Ethics
Committees or Institutional Review Boards. All patients pro-
vided written consent before study procedures or assessments
were performed.
The primary measures were MTD and DLTs. MTD was
defined as the highest dose at which one-third or fewer of
patients in a cohort experienced a DLT, which included grade
≥2 proteinuria, grade ≥3 nonhematologic toxicity (excluding
hypertension and pain), grade ≥3 thrombocytopenia with
bleeding, or grade 4 hematologic toxicity that was not clearly
due to progressive cancer. Secondary measures included the
pharmacokinetics of CEP-11981 after a single dose and
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multiple doses, the pharmacokinetic-pharmacodynamic pro-
file of CEP-11981, safety, and preliminary efficacy. The effi-
cacy endpoint was the proportion of patients who achieved
complete or partial response on study (minimum of 6 weeks)
according to Response Evaluation Criteria in Solid Tumors
(RECIST) guidelines [26].
Pharmacokinetic parameters calculated after a single dose
of CEP-11981 included area under the plasma drug concen-
tration versus time curve (AUC) from zero to infinity
(AUC0-∞), to the last measurable concentration (AUC0-t),
and to 24 h (AUC0–24); maximum observed plasma drug
concentration (Cmax); time to maximum observed plasma drug
concentration (Tmax); terminal elimination half-life (t½); and
predicted accumulation ratio (Rpred), which was defined as
AUC0–∞ (day 1, cycle 1)/AUC0–24 (day 1, cycle 1). Pharma-
cokinetic parameters calculated after multiple doses included
AUC0-t, Cmax, Tmax, and t½, and observed accumulation ratio
(Robs). Robs was defined as AUC for 1 dosing interval follow-
ing multiple doses (AUCτ; day 15, cycle 1)/AUC0–24 (day 1,
cycle 1). The pharmacokinetic analysis included patients who
received ≥1 dose of CEP-11981 and had ≥1 pharmacokinetic
value. Pharmacodynamics was assessed by VEGFR-2/KDR
inhibitory activity in response to CEP-11981 treatment.
The safety of CEP-11981 with dose escalation was
assessed by adverse events, clinical laboratory test results,
vital signs, electrocardiogram (ECG), physical examination,
and concomitant medication use. The safety analysis included
all patients who received ≥1 dose of CEP-11981. Adverse
events were recorded and graded according to the Common
Terminology Criteria for Adverse Events, version 3.0.
Patient evaluations
Physical examinations, urinalysis, ECG, and laboratory eval-
uations (including serum chemistry and hematology) were
performed at screening and on days 1, 2, 8, 15, 22, and 29
of cycle 1; on days 1, 15, and 29 of subsequent cycles; and at
the end-of-treatment follow-up visit (14 days after the last
dose). Adverse events were evaluated on days 2, 8, 15, and
22 of cycle 1; on days 1, 15, and 29 of every subsequent cycle;
and at the end-of-treatment follow-up visit. To evaluate pre-
liminary efficacy, tumors were measured by computed tomog-
raphy or contrast magnetic resonance imaging scans at screen-
ing and every 6 weeks.
Study treatment and dose escalation
Oral CEP-11981 was administered once daily for the first
28 days of each 42-day cycle. Initial dose escalation from
the starting dose of 3 mg/m2 was by 40 % increments. After
completion of additional toxicology studies and the prelimi-
nary analysis of plasma exposure in patients, the dose for the
fourth cohort was doubled from the third cohort and thereafter
the escalation followed a modified Fibonacci sequence. The
final dose levels were: 3.0, 4.2, 5.9, 11.8, 19.7, 29.6, 41.4,
55.0, 73.0, 97.4, and 126.6 mg/m2. The dose administeredwas
rounded to the smallest capsule strength available. Dosing for
a patient was to be stopped at the onset of a DLT and, at
resolution within 14 days, could be resumed at a dose equal to
50% of the patient’s current dose. In the event of DLTs in one-
third or more of patients receiving 3.0 mg/m2, the dose would
be reduced to 1.5 mg/m2. Dose escalation proceeded accord-
ing to the standard 3+3 design.
Pharmacokinetic studies
The venous blood samples for pharmacokinetic analysis were
collected on days 1 and 15 of dosing during cycle 1 immedi-
ately before dose administration and at 0.5, 1, 1.5, 2, 3, 4, 6, 8,
12 (this sample was optional and could be collected from 10 to
14 h), and 24 h postdose, as well as on days 8, 22, 29, and 43.
The venous blood samples for pharmacokinetic-
pharmacodynamic analysis were collected on days 1 and 15
of dosing during cycle 1 immediately before dose administra-
tion and at 1 h postdose, and on day 43. At each draw, 2
samples were obtained in 6-mL sodium heparinized
vacutainers. Plasma was obtained and stored at −70 °C until
shipment to the sponsor for analysis.
Pharmacodynamic bioassay
A bioassay with engineered chimeric porcine aortic endothe-
lial (PAE) cell lines stably expressing a TrkA-VEGFR-2/KDR
domain was used to evaluate human plasma-associated shifts
in cellular IC50 for CEP-11981 inhibition of ligand-stimulated
VEGFR-2/KDR phosphorylation. Plasma samples for the
bioassay were obtained 1 h postdose and on days 1 and 15;
they were collected from patients across cohorts.
Results
Patients
Forty-three patients with advanced, refractory/relapsed solid
tumors were enrolled in the study (Fig. 1) between September
2007 and February 2011. Demographics and baseline charac-
teristics are listed in Tables 1 and 2. Patients were heavily
pretreated, with all patients having received prior radiotherapy
(100 %), chemotherapy (100 %), and surgery (100 %). The
most common cancers in this study population were colorectal
(19%) and lung (19%). Thirty-five patients (81%) completed
1 treatment cycle and 17 completed ≥2. During the first cycle,
8 patients discontinued due to adverse events (n=4) and
disease progression (n=4). Seventeen patients (40%) received
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≥2 cycles. Among patients who received ≥1 cycle, 35 (81 %)
discontinued, most commonly for disease progression (31
patients, 72 %).
Dose escalation and MTD
DLTs did not occur at lower doses and occurred only in
the 126.6 mg/m2 dose cohort. The first 2 patients in the
cohort had DLTs and recruitment at this dose level was
stopped. One patient experienced grade 4 neutropenia
and the second patient experienced grade 2 exertional
dyspnea, grade 2 chest heaviness, and grade 3 new T-
wave inversion. The second patient with colorectal can-
cer (and without a history of active cardiovascular dis-
ease), was hospitalized for cardiac work-up with proba-
ble ischemia, and the ECG changes and chest discom-
fort resolved. Three additional patients were added to
the 97.4 mg/m2 cohort. As no DLTs were observed in
the 97.4 mg/m2 cohort, this dose was determined to be
the MTD.
Exposure
All patients who received ≥1 dose of study drug (n=43) were
evaluated for safety. These patients received between 1 and 10
treatment cycles of CEP-11981, with a median of 28 days
(range, 5–250) of treatment (Table 3). The overall median
relative dose intensity across all cycles was 96.8 % (range,
1.6 % to 107.5 %). Four patients received ≥5 cycles: 1 in the
3.0 mg group (8 cycles, endometrial cancer), 1 in the 29.6 mg
Screened 56













Not enrolled  13
   Inclusion criteria not met 10
   Consent withdrawn 1
   Other 2




























Fig. 1 Patient Disposition. Shows that 56 patients were screened for the
study and 43 patients enrolled. 10 patients did not meet inclusion criteria.
Enrolled patients received CEP-11981 at dose levels ranging from
3.0 mg/m2 to 126.6 mg/m2; 8 patients discontinued treatment during
cycle 1 due to adverse event (n=4) or disease progression (n=4). The
remaining 35 patients discontinued after ≥1 treatment cycle due to disease
progression (n=31), adverse event (n=2), or consent withdrawal (n=2)
Table 1 Patient demographics and baseline characteristics
Variable Total (N=43)








Median years since first cancer diagnosis (range) 3.2 (0.6–17.8)
Best response to prior cancer therapy, n (%)
Complete 3 (7)
Partial 7 (16)
Stable disease 23 (53)
Disease progression 7 (16)
Missing 3 (7)
Most common tumor type, n (%)
Colorectal 8 (19)
Lung 8 (19)
Prior radiation therapy 43 (100)
Prior chemotherapya 43 (100)




5-Fluorouracil, irinotecan, oxaliplatin 11 (26)
Carboplatin, docetaxel 10 (23)




Range of cycles per regimen 2–29
Prior surgery 43 (100)
a Names as recorded in listing of prior therapies
ECOG, Eastern Cooperative Oncology Group
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group (6 cycles, head), 1 in the 55.0 mg group (10 cycles,
lung), and 1 in the 97.4 mg group (5 cycles, lung).
Adverse events
All 43 patients experienced ≥1 adverse event, and 38 patients
(88.3 %) were deemed to have had adverse events possibly,
probably, or definitely related to study drug. The most fre-
quently reported adverse event of any grade was fatigue (n=
22, or 51%). Other frequently reported adverse events (≥20%
of patients) were nausea (47 %), diarrhea (33 %), decreased
appetite (33 %), abdominal pain (30 %), back pain (28 %),
vomiting (28 %), constipation (28 %), headache (28 %), diz-
ziness (28%), and dyspnea (23%). These adverse events were
reported at a similar frequency between dosage cohorts, and
no relationship with dose was evident. Most adverse events
were grade 1 or 2.
Grade 3 or 4 adverse events occurred in 16 (37 %)
patients across dosing cohorts (14 [32.6 %] grade 3 and
2 [4.7 %] grade 4). Treatment-related grade 3 or 4
adverse events were most frequent in the 97.4 mg/m2
cohort (Table 4). Grade 3 or 4 laboratory hematologic
toxicities were reported in 8 (18.6 %) patients across
dosage cohorts. The most common grade 3 or 4 labo-
ratory hematologic toxicity was lymphopenia, which
occurred in 8 patients and across dosage cohorts (5.9,
29.6, 55.0, 97.4, and 126.6 mg/m2). Grade 4 leukopenia
occurred in 1 patient in the 126.6 mg/m2 cohort. Grade
3 or 4 neutropenia also occurred in 2 patients in the
97.4 mg/m2 cohort (grade 3) and in 1 patient in the
126.6 mg/m2 cohort (grade 4).
Serious adverse events occurred in 12 patients; most were
deemed unlikely or not related to CEP-11981. Three patients
(1 patient in the 97.4 mg/m2 cohort and 2 patients in the
126.6 mg/m2 cohort) experienced serious adverse events that
were categorized as possibly or definitely related to CEP-
11981: pyrexia, hemolytic anemia, hyperbilirubinemia, dys-
pnea, neutropenia, ECG change, and chest discomfort. No
deaths occurred during the study.
Pharmacokinetics
There was a relationship between drug dose and exposure
(Cmax and AUC) after administration of a single dose
(Fig. 2a). Dose proportionality could not be reliably assessed
because of the extent of interpatient variability and small
increments in dosages between the cohorts (Fig. 2a). There
was interpatient variability of absorption after administration
of a single dose, but there did not appear to be a relationship
between dose and Tmax after administration of a single dose
across cohorts (Table 5). The mean plasma concentration-
versus-time profiles after single-dose administration (Fig. 3a)
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achieving peak plasma concentration, with an initial phase of
drug distribution and a slower terminal elimination phase.
Other patients had a monophasic decline, which was likely
due to a prolonged period of absorption. The mean t½ after a
single-dose administration was between 8 and 10 h (Table 5).
Pharmacokinetic parameters of CEP-11981 after the ad-
ministration of several doses are summarized in Table 5,
Figs. 2b and 3b. Multiple-dose administration with CEP-
11981 also demonstrated a relationship between increased
dosage and increased exposure (ie, Cmax and AUC) (Table 5,
Fig. 2b). Inter- and intrapatient variability after administration
of multiple doses was also demonstrated, with no relationship
between dosage and Tmax after administration of multiple
doses. The median Tmax after multiple administrations ranged
from 1.5 to 8 h across cohorts (Table 5). The mean plasma
concentration-versus-time profiles after multiple administra-
tions of CEP-11981 (Fig. 3b) were qualitatively similar to
those after a single-dose administration (Fig. 3a). After mul-
tiple administrations, there were also patients who had a
biphasic decline from the peak plasma concentration and other
patients who had a monophasic decline; the mean t½ ranged
from 8 to 10 h after multiple administrations of CEP-11981.
The shapes of the mean plasma concentration-versus-time
profiles for multiple- versus single-dose administrations
showed that the absolute plasma concentrations were slightly
higher after receipt of multiple doses reflecting the attainment
of steady state.
Pharmacodynamic bioassay
An ex vivo bioassay to evaluate the magnitude of cellular
VEGFR-2/KDR kinase inhibition was conducted using plas-
ma samples from the 27 patients across all cohorts who had
samples with sufficient volume for analysis. The data
were normalized relative to predose baseline levels of
cellular VEGFR-2/KDR kinase inhibition. Less than
50 % inhibition of VEGFR-2/KDR kinase was achieved
when using plasma samples from the lower dose cohorts
(ie, 3.0, 4.2, 5.9, 11.8, and 19.7 mg/m2), which are
shown in quintiles 1 and 2 of Fig. 4. Mean cellular
VEGFR-2/KDR inhibition was observed beginning with
the 29.6 and 55 mg/m2 dose cohorts (41 % to 60 %
inhibition [quintile 3] and 61 % to 80 % inhibition
[quintile 4]), respectively. Normalized mean cellular
VEGFR-2/KDR inhibition was more pronounced (81 %
or greater [ie, quintile 5]) and appeared to be exposure-
related in plasma samples primarily in the 73.0, 97.4,
and 126.6 mg/m2 cohorts, although inhibition was
variable.
























































0 20 40 60 80 100 120 140
CEP-11981 Dose (mg/m2)

























































0 20 40 60 80 100 120 140
CEP-11981 Dose (mg/m2)
Fig. 2 Individual Subject and
Mean Values for Cmax and AUC
(n=2–n=9/dose level)a. Depicts
that there is a relationship
between drug dose and exposure
(Cmax and AUC) after
administration of a single dose of
CEP-11981 on day 1 (in Fig. 2a)
and after multiple-dose
administration of CEP-11981 at
day 15 (in Fig. 2b). aOpen
symbols represent the individual
subject values; closed symbols
represent the mean values. AUC0–
24, area under the plasma drug
concentration by time curve from
0 to 24 h; AUCτ, area under the
plasma drug concentration-time
curve for 1 dosing interval; Cmax,
maximum plasma drug
concentration
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Tumor response
Out of 43 patients who received ≥1 dose of study drug, 37
patients were evaluated for tumor response. Although no
enrolled patients had complete or partial response according
to RECIST criteria, 19 of 37 (51 %) patients evaluated for
tumor response had stable disease at ≥6 weeks; 18 had disease
progression. The frequency of stable disease (defined as
<30 % decrease and <20 % increase in the sum of the longest
diameter of the target lesions) was higher in cohorts receiving
doses ≥73.0 mg/m2 (8 of 14 [57.1 %] patients) compared with
cohorts receiving ≤55.0 mg/m2 (11 of 29 [37.9 %] patients)
(Fig. 5).
Discussion
CEP-11981 was acceptably tolerated up to a dose of 97.4 mg/
m2, which was determined to be the MTD. The appropriate-
ness of this dose is consistent with findings ex vivo VEGFR-
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0 4 8 12 16 20 24
Time After Dose Administration (hr) 
3.0 mg/m2 (n=3) 4.2 mg/m2 (n=3) 5.9 mg/m2 (n=5) 11.8 mg/m2 (n=3)
19.7 mg/m2 (n=3) 29.6 mg/m2 (n=4) 41.4 mg/m2 (n=3) 55.0 mg/m2 (n=4)
73.0 mg/m2 (n=3) 97.4 mg/m2 (n=9) 126.6 mg/m2 (n=2)
Fig. 3 Mean (SE) Plasma Concentration-Versus-Time Profiles. Shows
that some patients demonstrated a biphasic decline after achieving peak
plasma concentration and other patients showed a monophasic decline
after single-dose administration (Fig. 3a) and that the mean plasma
concentration-versus-time profile after multiple-dose administrations of
CEP-11981 (Fig. 3b) was qualitatively similar to that of single-dose
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1– 20% 21– 40% 41– 60% 61– 80% 81–100%
Inhibition Score (Quintile)
Fig. 4 Ex Vivo Bioassay Analysis of Cellular VEGFR-2/KDR Kinase
Inhibition in TrkA-VEGFR-2/KDR Chimeric PAE Cells (N=27). Pre-
sents the magnitude of cellular VEGFR-2/KDR kinase inhibition using
plasma samples from patients across all cohorts grouped by inhibition-
score quintile. Normalized mean cellular VEGFR-2/KDR inhibition ap-
peared to be exposure-related, although inhibition was variable. VEGFR-
2/KDR, vascular endothelial growth factor receptor, subtype 2/KDR;

























3.0 4.2 5.9 11.8 19.7 29.6 41.4 55.0 73.0 97.4 126. 6





















Fig. 5 Best Overall Tumor Response Per Cohorta at ≥6 Weeks. Depicts
tumor response, with bars above the x-axis indicating patients (n=19)
who achieved stable disease and bars below the x-axis indicating patients
(n=18) with disease progression. aNo patient achieved complete or partial
response. bSix patients were not evaluable at dosages of 19.7, 29.6, 55.0,
and 126.6 mg/m2 (n=1, each); 97.4 mg/m2 (n=2)
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2/KDR inhibition in the quintile 5 plasma samples from
patients receiving 97.4 mg/m2 (3 of 5 patients) and
126.6 mg/m2 (1 of 1) and that the best response (stable
disease) occurred more frequently in cohorts receiving
≥73.0 mg/m2 (8 of 14, 57.1 %). In addition to the DLT of
neutropenia in the patient treated at 126.6 mg/m2, 2 patients
treated at 97.4 mg/m2 developed grade 3 neutropenia (1
patient in cycle 1 only, the other patient in a subsequent cycle
only) that showed a temporal relationship to cycles of CEP-
11981. Although the DLTs may be due to multiple targets of
CEP-11981 (such as Aurora A), the importance of this obser-
vation is difficult to assess since only 3 of 9 patients treated at
97.4 mg/m2 received 2 or more cycles of treatment. Therefore,
97.4 mg/m2 was the MTD and can be considered a provision-
ally recommended phase II dose, but long-term tolerability
remains to be determined.
Like CEP-11981, a number of other VEGFR-TKIs exhib-
ited moderate pharmacokinetic variability in phase I and/or
dose-escalation studies [27–30]. CEP-11981 potently and
specifically inhibits VEGFR-1 and VEGFR-2, with IC50
values of 3 and 4 nM, respectively, in vitro [25]. In a previous
study, targeted therapies were compared based on reported
IC50 values for VEGFR-1 and VEGFR-2; sunitinib had IC50
of 10 nM (using murine NIH-3T3 cells) and 40 nM (using
human umbilical vein endothelial cells [HUVEC]) for
VEGFR-2 [31] and pazopanib had IC50 for VEGFR-2 of 8
nM (using HUVEC), while assays of VEGFR-1 were not
done [32]. Pharmacodynamic bioassays showed inhibition of
VEGFR-2 at doses with acceptable tolerability in this study.
However, the neutropenia observed in patients at doses above
73.0 mg/m2, and its temporal relationship to CEP-11981
administration, suggest the inhibition of an unknown kinase.
Laboratory studies have shown CEP-11981 inhibits Aurora A
[25] and it is possible that this may account for the
myelosuppression observed. There was intra- and interpatient
variability after administration of multiple doses of CEP-
11981 in patients with advanced solid tumors in this phase I
study. The likelihood of a patient achieving responsiveness to
therapy could not be predicted.
The recent controversy surrounding ponatinib highlights a
growing body of evidence that most if not all TKIs sufficiently
studied may increase patients’ risk of adverse cardiovascular
events, including hypertension, thrombotic events, and QT-
interval prolongation [33–35]. Nevertheless, product informa-
tion for approved TKIs includes warnings about adverse car-
diovascular events, and surveillance to determine how to best
manage these risks is ongoing [33]. Some TKIs also are
associated with treatment-related hepatotoxicity (as indicated
by elevated ALT, AST, and total bilirubin) [36]. Labeling for
lapatinib, pazopanib, and sunitinib, among others, includes
warnings about hepatotoxicity [36]. In the present CEP-11981
study, 8 treatment-related events were reported. The most
common grade 3/4 events affecting ≥5 % of patients across
all groups were lymphopenia (19 %), neutropenia (7 %), and
abdominal pain or back pain (7 % each). Regarding TKI-
associated cardiovascular adverse events (QT interval prolon-
gation, left ventricular dysfunction, and hypertension [34]), this
CEP-11981 study reported 1 (2 %) patient with hypertension
and 1 patient (2 %) with ECG changes. One patient receiving
CEP-11981 (97.4 mg/m2) reported hyperbilirubinemia, which
resolved after the patient discontinued the study. Overall, the
tolerability profile of CEP-11981 appears to be promising;
however, current evidence of efficacy is modest, and the com-
pound is no longer in development by the sponsor.
In conclusion, CEP-11981 was well tolerated at doses
between 3.0 and 97.4 mg/m2, with occasional routine dose
reductions and with DLTs observed at 126.6 mg/m2. The
MTD of CEP-11981 was determined to be 97.4 mg/m2. These
events as well as DLTs and potentially treatment-related seri-
ous adverse events were generally reported in the highest-dose
cohorts (97.4 [MTD] and 126.6 mg/m2). No patient experi-
enced complete or partial response, 19 patients (44 % of the
intent-to-treat population, or 51 % of patients with efficacy
data) had stable disease at ≥6 weeks, primarily in the higher-
dose cohorts. This study supports the dose-dependent biolog-
ical effects of TKIs and the need for dose-finding efforts in
order to achieve biological and clinical effective doses with
this class of agents. The challenge of defining the optimal
patient population for agents targeting the tumor microenvi-
ronment remains an opportunity.
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